Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market Insight
Published: 18 May 2026 | Report Format: Electronic (PDF)
The Canada anti-vascular endothelial growth factor therapeutics market size is growing at a 0.54% CAGR, driven by the increasingly adopting anti-VEGF biologics, biosimilars, and sustained-release systems for improved long-term patient outcomes.
Canada Anti-vascular Endothelial Growth Factor Therapeutics Market Insights Forecasts to 2035
- The Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Was Estimated at USD 451.4 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 0.54% from 2025 to 2035
- The Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market Size is Expected to Reach USD 476.3 Million by 2035
Notable Insights for Canada Anti-vascular Endothelial Growth Factor Therapeutics Market
- By drug types, Aflibercept gained almost 33-35% of market share in the Canada anti-vegf therapeutics market in 2025 due to its increasing usage in retinal diseases and long-term ocular therapies.
- By application, Age-related macular degeneration (AMD) is predicted to have 37-38% of market share in 2025, owing to Canada's growing aging population, increasing incidence rate of retinal diseases, and increased demand for advanced treatment.
- The Health Department of Canada regulates biologic drug treatments, ophthalmic drug treatments, and targeted cancer drug treatments by setting stringent pharmaceutical regulations for their safety and effectiveness.
- Canadian Institute of Health Research funds research studies on ophthalmology, oncology, and biological therapies that drive advancements in health science and improve advanced treatment outcomes.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Canada anti-vascular endothelial growth factor therapeutics market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment Market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the Market.
Top Companies in Canada Anti-vascular Endothelial Growth Factor Therapeutics Market
-
- F. Hoffmann-La Roche Ltd.
- Regeneron Pharmaceuticals, Inc.
- Novartis AG
- Bayer AG
- Pfizer Inc.
- Amgen Inc.
- Samsung Bioepis Co., Ltd.
- Biogen Inc.
- Coherus BioSciences, Inc.
- Outlook Therapeutics, Inc.
Recent Developments:
- In April 2025, Canada anti-vegf therapeutics market advanced with CAD 1.8 billion ophthalmology investments, expanding aflibercept use, biosimilars adoption, and AI-enabled retinal imaging systems, improving disease detection, treatment precision, and patient outcomes nationwide in Canada.
Market Segmentation:
Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Drug Type
-
- Ranibizumab
- Bevacizumab
- Aflibercept
- Brolucizumab
- Others
Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Application
-
- Age-Related Macular Degeneration
- Diabetic Retinopathy
- Cancer Treatment
- Retinal Vein Occlusion
- Others
Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Route of Administration
-
- Intravitreal Injection
- Intravenous Administration
- Others
Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market, By End User
-
- Hospitals
- Ophthalmology Clinics
- Cancer Treatment Centers
- Others
Expert Views:
The Canada anti-vascular endothelial growth factor therapeutics market is projected to experience strong growth for the long term due to innovations in biologic drugs, advancements in precision medicines, and modernization of ophthalmic care systems in the Canadian healthcare industry. Increasing interest in vascular disease treatments, biologic treatment options, and chronic disease treatments is anticipated to be a key driver for the market’s growth.